Skip to Main Content

After months of testing, the Food and Drug Administration reported finding unacceptable levels of a possible carcinogen in some metformin diabetes pills, marking the third time in two years that the same impurity was discovered in a widely used medicine.

In a brief statement, the agency noted that traces of a possible carcinogen known as NDMA were found in extended-release versions of metformin, but not in immediate-release versions. As a result, the FDA is contacting manufacturers to take “quick and appropriate action,” but did not say whether any recalls have so far occurred.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • Ed, could you please share the link for the FDA communication? I can see lots of reporting on this issue, but can’t find the actual FDA communication. Thanks!

    • Hi Rob

      Maybe I missed it, but I haven’t seen one. What I learned from the FDA came in the form an email sent me. If there is a communication, I will update the post, whenever one may be issued or I find it.

      Regards
      ed at pharmalot

Comments are closed.